CureVac (NASDAQ:CVAC) Short Interest Update

CureVac (NASDAQ:CVAC) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totalling 4,850,000 shares, an increase of 19.5% from the March 15th total of 4,060,000 shares. Currently, 5.2% of the company’s stock are short sold. Based on an average daily volume of 812,400 shares, the days-to-cover ratio is presently 6.0 days.

Hedge Funds Weigh In On CureVac

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Barclays PLC purchased a new position in shares of CureVac in the third quarter worth $67,000. Public Employees Retirement System of Ohio purchased a new position in CureVac in the 3rd quarter worth about $91,000. Jane Street Group LLC lifted its stake in CureVac by 239.0% during the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after acquiring an additional 55,867 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of CureVac by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock valued at $162,000 after acquiring an additional 4,425 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its stake in shares of CureVac by 61.8% in the fourth quarter. Quadrant Capital Group LLC now owns 50,016 shares of the company’s stock worth $171,000 after acquiring an additional 19,098 shares during the period. 17.26% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $16.00 price objective on shares of CureVac in a research report on Friday, February 14th.

CureVac Stock Up 1.9 %

CureVac stock traded up $0.06 during mid-day trading on Monday, reaching $3.18. The stock had a trading volume of 304,241 shares, compared to its average volume of 807,818. CureVac has a one year low of $2.22 and a one year high of $5.28. The company has a 50-day moving average price of $3.08 and a two-hundred day moving average price of $3.17. The company has a market capitalization of $713.39 million, a price-to-earnings ratio of 5.78 and a beta of 2.48. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19.

CureVac (NASDAQ:CVAC) last issued its earnings results on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). CureVac had a return on equity of 21.98% and a net margin of 20.72%. The firm had revenue of $15.44 million during the quarter, compared to the consensus estimate of $6.40 million. On average, analysts expect that CureVac will post 0.72 EPS for the current fiscal year.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.